RT Journal Article
SR Electronic
T1 Eight-Fold Increased COVID-19 Mortality in Autosomal Dominant Tubulointerstitial Kidney Disease due to <em>MUC1</em> Mutations: An Observational Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.03.24309887
DO 10.1101/2024.07.03.24309887
A1 Kidd, Kendrah O.
A1 Williams, Adrienne H.
A1 Taylor, Abbigail
A1 Martin, Lauren
A1 Robins, Victoria
A1 Sayer, John A.
A1 Olinger, Eric
A1 Mabillard, Holly R.
A1 Papagregoriou, Gregory
A1 Deltas, Constantinos
A1 Stavrou, Christoforos
A1 Conlon, Peter J.
A1 Hogan, Richard Edmund
A1 Elhassan, Elhussein A.E.
A1 Springer, Drahomíra
A1 Zima, Tomáš
A1 Izzi, Claudia
A1 Vrbacká, Alena
A1 Piherová, Lenka
A1 Pohludka, Michal
A1 Radina, Martin
A1 Vylet’al, Petr
A1 Hodanova, Katerina
A1 Zivna, Martina
A1 Kmoch, Stanislav
A1 Bleyer, Anthony J.
YR 2024
UL http://medrxiv.org/content/early/2024/07/04/2024.07.03.24309887.abstract
AB Background MUC1 and UMOD pathogenic variants cause autosomal dominant tubulointerstitial kidney disease (ADTKD). MUC1 is expressed in kidney, nasal mucosa and respiratory tract, while UMOD is expressed only in kidney. Due to haplo-insufficiency ADTKD-MUC1 patients produce approximately 50% of normal mucin-1.Methods To determine whether decreased mucin-1 production was associated with an increased COVID-19 risk, we sent a survey to members of an ADTKD registry in September 2021, after the initial, severe wave of COVID-19. We linked results to previously obtained ADTKD genotype and plasma CA15-3 (mucin-1) levels and created a longitudinal registry of COVID-19 related deaths.Results Surveys were emailed to 637 individuals, with responses from 89 ADTKD-MUC1 and 132 ADTKD-UMOD individuals. 19/83 (23%) ADTKD-MUC1 survey respondents reported a prior COVID-19 infection vs. 14/125 (11%) ADTKD-UMOD respondents (odds ratio (OR) 2.35 (95%CI 1.60-3.11, P = 0.0260). Including additional familial cases reported from survey respondents, 10/41 (24%) ADTKD-MUC1 individuals died of COVID-19 vs. 1/30 (3%) with ADTKD-UMOD, with OR 9.21 (95%CI 1.22-69.32), P = 0.03. The mean plasma mucin-1 level prior to infection in 14 infected and 27 uninfected ADTKD-MUC1 individuals was 7.06±4.12 vs. 10.21±4.02 U/mL (P = 0.035). Over three years duration, our longitudinal registry identified 19 COVID-19 deaths in 360 ADTKD-MUC1 individuals (5%) vs. 3 deaths in 478 ADTKD-UMOD individuals (0.6%) (P = 0.0007). Multivariate logistic regression revealed the following odds ratios (95% confidence interval) for COVID-19 deaths: ADTKD-MUC1 8.4 (2.9-29.5), kidney transplant 5.5 (1.6-9.1), body mass index (kg/m2) 1.1 (1.0-1.2), age (y) 1.04 (1.0-1.1).Conclusions Individuals with ADTKD-MUC1 are at an eight-fold increased risk of COVID-19 mortality vs. ADTKD-UMOD individuals. Haplo-insufficient production of mucin-1 may be responsible.Competing Interest StatementAJB has received compensation as follows: advisory board, Horizon Pharma; speaker, Natera; author, UpToDate; advisor, First Faculty of Medicine, Charles University; royalty; Sail Bio; patent for UMOD genetic diagnosis. PJC has received funding from Astra Zeneca, Bohringher, Hansa, and medical advisory board fees. KOK, AHW, AT, AK, LM, VR, APR-C, JAS, EO, HRM, GP, CD, CS, REH, EE, DS, CI, AV, LP, TZ, MP, MR, PV, KH, MZ, and SK have nothing to disclose.Funding StatementThis study was funded by by NIH-NIDDKUO1 DK-103225, the Black Brogan Foundation, The Slim Health Foundation, and Soli Deo Gloria.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Wake Forest University Health Sciences gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors